IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

IceCure Medical Ltd. has announced a private placement agreement with a single healthcare-focused institutional investor, aiming to raise approximately $5.5 million. The transaction, which involves the sale of 1,833,334 ordinary shares priced at $3.00 each, is expected to close on or about June 18, 2026. The offering also includes Series D and Series E Warrants, each allowing the purchase of an equivalent number of ordinary shares at the same price.

IceCure Medical, headquartered in Caesarea, Israel, specializes in the development of minimally invasive cryoablation technology, which targets tumors by freezing them, offering a less invasive alternative to traditional surgical methods. The company's flagship product, the ProSense® system, is designed for the treatment of various types of tumors, including those in the breast, kidney, bone, and lung. With its innovative approach, IceCure aims to provide effective treatment options that can be performed quickly and safely, appealing to both patients and healthcare providers.

The strategic rationale behind this fundraising initiative appears to be focused on bolstering IceCure's working capital and supporting its ongoing corporate activities. The funds raised will enable the company to enhance its operational capabilities and potentially expand its market presence. Additionally, the pricing of the shares at a premium to the previous Nasdaq closing price indicates investor confidence in IceCure’s future prospects, despite the inherent risks associated with biotech investments.

This fundraising comes at a time when the healthcare sector, particularly in the biotech and medical device domains, is experiencing significant interest from institutional investors. The demand for innovative medical technologies that improve patient outcomes is driving investment activity, as healthcare systems worldwide seek more effective and less invasive treatment options. IceCure's focus on cryoablation technology aligns well with these trends, positioning the company to capitalize on the growing market for minimally invasive therapies.

Looking ahead, the successful completion of this private placement could enhance IceCure's financial stability and support its strategic initiatives. As the company continues to advance its product offerings and expand its market reach, it may attract further investment interest. The broader implications of this transaction highlight the ongoing momentum in the healthcare investment landscape, where innovative companies like IceCure are poised to play a critical role in shaping the future of medical treatment.